The experts of the vaccine presentation of the Interterritorial Health Council will analyze the expansion of the age ranges to which the booster dose against COVID-19 will be administered.
The text emphasizes the current epidemiological situation, with an increase in the incidence rate and hospitalizations and deaths from COVID-19 in the sixth pandemic wave. In addition to the appearance and spread of new variants of concern such as Ómicron, “Makes it necessary to consider the administration of booster doses of the vaccine against COVID-19 to larger population groups to increase protection.”
After prioritizing the vaccination of people aged 60 and over and people under 60 vaccinated with Vaxzevria (AstraZeneca), it would be convenient to start booster doses for people aged 40- 59 years which is approximately 15 million people in Spain.
Of the more than five million first doses of Vaxzevria (AstraZeneca) administered, 70.6% were to persons between 60 and 69, 21.3% to people between 50 and 59 years old, and the remaining 8.3% to people between 18 and 49 years old. Only 10% of these people received a heterologous regimen (Vaxzevria-Pfizer). 71% of the people vaccinated with the heterologous regimen were between 50 and 59 years old.
According to experts, people vaccinated with the two doses of AstraZeneca have shown in different effectiveness studies at national and international levels lower effectiveness against infection (symptomatic or asymptomatic) and hospitalizations than mRNA vaccines. This means that the third dose of either Pfizer or Moderna given to people vaccinated with AstraZeneca will increase their immunity to the coronavirus.